Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Pilot Study to Evaluate the Feasibility and Safety of Cytomegalovirus-Specific, Anti-HIV Chimeric Antigen Receptor (CMV-HIV CAR) T Cells in People Living With HIV

Next Previous
Trial Profile

A Pilot Study to Evaluate the Feasibility and Safety of Cytomegalovirus-Specific, Anti-HIV Chimeric Antigen Receptor (CMV-HIV CAR) T Cells in People Living With HIV

Status: Recruiting
Phase of Trial: Phase 0

Latest Information Update: 25 Feb 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Cytomegalovirus/Human-immunodeficiency-virus-CAR-T-cell-therapy-Fortress-Biotech (Primary)
  • Indications HIV-1 infections
  • Focus Adverse reactions; First in man

Most Recent Events

  • 21 Nov 2024 Planned initiation date changed (estimated date for recruitment of the first subject) from 30 Oct 2024 to 30 Jan 2025.
  • 28 Aug 2024 Planned initiation date changed from 30 Jul 2024 to 30 Oct 2024.
  • 05 Aug 2024 New trial record

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top